3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
9
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Leukemia
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Non-small Cell Lung Cancer Metastatic
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Meningioma
1
Melanoma
1
Lymphoma
1
Fallopian Tube Neoplasms
1
Exanthema
1
Endometrial Neoplasms
1
Disease Progression
1
Diarrhea
1
Chondrosarcoma
1
Carcinoma, Squamous Cell
1
CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
1
Advanced Gastric Cancer
1
Advanced Cancer
1
Advanced Breast Cancer
1
Interventions
Pemetrexed
4
pembrolizumab
3
Carboplatin
3
Vinorelbine
2
Gemcitabine
2
vistusertib
1
vandetanib
1
spartalizumab
1
sotorasib
1
sintilimab
1
olaparib
1
icotinib
1
durvalumab
1
dacomitinib
1
capivasertib
1
aumolertinib
1
Radiosurgery
1
Platinum
1
MLN 8237
1
Injections
1
Immune Checkpoint Inhibitors
1
Gefitinib
1
GC Temporary Stopping
1
Erlotinib Hydrochloride
1
Drug Therapy
1
Cisplatin
1
Bevacizumab
1
AZD4547
1
AZD 8931
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Non-small Cell Lung Cancer Metastatic
×
capivasertib
×
Clear all
NCT02117167
2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2
Completed
999 enrolled